Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Sensitizing Potential of HAT1 Topical Products
NCT03406117Phase 4Completed
- Sponsor
- Haus Bioceuticals
- Start
- Apr 2016
- Primary completion
- Jun 2016
- Modality
- Botanical Extract, Emollient
01
Overview
Phase 4, randomised, single-blind trial of Metaderm in atopic dermatitis (AD) and psoriasis (3 arms), sponsored by Haus Bioceuticals. Primary endpoint: Visual assessment (Patch assessment). Started Apr 2016; status: completed.
02
Drugs
Metaderm
03
Conditions
atopic dermatitis (AD)psoriasis
Beyond the preview
Go deeper on NCT03406117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03406117.